Education:

Texas A&M University: Biomedical Science, B.S.

About:

Matthew Wagener currently serves as the Vice President of Clinical Operations at Proxima Clinical Research, Inc. Proxima is a contract research organization focused on assisting emerging pharmaceutical and medical device companies in clinical product development.

Matt has over 15 years of industry experience working across multiple life science businesses in key areas including clinical operations, business operations, and business development.

Prior to joining the Proxima team, he was a member of the executive team and the Sr. Director of Corporate Operations at MedSource, a CRO focused on Oncology, Neurology, and Rare Diseases. While at MedSource, Matt successfully managed corporate operations and business development through high growth period (57% CAGR over five years) building operations to support growth. Prior to MedSource, he held several management positions at McKesson Specialty Health / US Oncology. At US Oncology Matt led clinical and business operations for the launch of their oncology CRO through start-up, full service clinical trial operations, and business acquisition. Prior to managing the CRO business unit at US Oncology, he led clinical development for the Lung, GI, Hematology, and Radiation Oncology research programs. He also held other research positions at the University of Texas Medical Branch in Galveston in the department of Orthopedic Surgery and MD Anderson Cancer Center in the department of Radiation Oncology.  

Matt received his degree in biomedical science from Texas A&M University.  Since starting his career in research, he has worked in key sections of basic and clinical research from bench to bedside to management.

Positions and Honors:

Proxima Clinical Research, Inc., Houston, Texas
Vice President Clinical Operations

MedSource, Houston, Texas (acquired by Ergomed PLC)
Senior Director Corporate Operations

McKesson, Inc., Woodlands, Texas
Director, Research Business Development and Alliances

US Oncology Clinical Development, LLC, Woodlands, Texas (acquired by McKesson)
Associate Director, CRO Clinical and Business Operations

Manager, Clinical and Business Development

US Oncology Research, Inc., Woodlands, Texas (acquired by McKesson)
Manager, Clinical Development

University of Texas Medical Branch, Galveston, Texas
Research Coordinator

MD Anderson Cancer Center, Houston, Texas
Research Assistant

Contributions to Science:

Mr. Wagener has played an important role in the development of the following medical products:

  1. In vitro diagnostic device for detection of SARS-CoV-2 (COVID-19)
  2. Medical device for treatment of intracranial bifurcation aneurysms
  3. Medical device for liver transplant
  4. Medical device for prostate cancer ablation
  5. In vitro diagnostic device for detection of SARS-CoV-2 (COVID-19)
  6. Medical device (noninvasive transcutaneous spinal cord stimulation) to enhance upper extremity function
  7. Medical device for imaging and analysis of tissue during breast cancer surgery
  8. First in human dose finding study of investigational drug product
  9. Pre-IND and IND filing for biologic product for solid tumors and lung cancer
  10. Pre-IND filing for drug product for COVID-19 treatment
  11. Drug product for tardive dyskinesia  
  12. CAR-T therapy for oncology
  13. Stem cell therapy for oncology
  14. Bleed detection and monitoring device during endovascular procedures
  15. Numerous studies for lung cancer, gastrointestinal cancers, and hematologic malignancies  
  16. Medical devices for total hip replacement/arthroplasty
  17. Medical device for pain management following total knee replacement/arthroplasty
  18. Medical device for diabetic foot ulcers
  19. Medical device for wound care
Additional Information:
OriginallY From:
Humble, TX
Fun Fact:
Matt enjoys spending time with is family, playing guitar, and watching Aggie football.
Recent Updates
Knowledge Base Contributions
Frequently Asked Questions
Glossary Terms